TABLE 2

Observed dog in vivo clearance and prediction of dog in vivo clearance from dog hepatocyte CL_{int, met} and CL_{int, uptake}

	CL_{int, met}	fu_p	fu_inc	R_b	Renal Clearance^{^a}	Observed Nonrenal Clearance^{^a}	Predicted CL_dog from Metabolic CL_int	Predicted CL_dog from Dog Hepatocyte CL_{int, uptake}
	μl · min⁻¹ · 10⁶ cells⁻¹				ml · min⁻¹ · kg⁻¹
Glibenclamide	<3	0.006	0.76	0.5	<0.01 (<0.01, <0.01)	1.0 (1.0, 0.9)	<1	8.4
Olmesartan	<1.3	0.012	1	0.5	2.6 (3.8, 1.4)	10 (9.8, 11)	<0.8	4.4
Pitavastatin	3.3	0.029	0.91	0.6	0.35 (0.3, 0.4)	6.8 (5.0, 8.4)	3	15
Pravastatin	1.2	0.39	0.97	0.6	3.4 (4.1, 2.7)	9.0 (8.3, 9.6)	7.5	13
Valsartan	2	0.013	0.99	0.7	0.15 (0.1, 0.2)	8.3 (11, 5.6)	1.3	7.5